Your orphan drug is approved in Europe. Turkish patients still cannot get it.
We generate the local epidemiology and real-world evidence that licensing and reimbursement in Turkey require.
The problem
Reimbursement files are often rejected or delayed for lack of local patient numbers and burden-of-disease data.
Why Turkey
A large market for recessive disease.
85 million people, with high rates of consanguinity. 1
Named patient imports today.
Demand already exists; a licence and reimbursement turn it into a market.
Evidence builds fast.
Concentrated referral centres make registry recruitment efficient.
What we do
- Epidemiology and patient-finding studies for your indication
- Disease registries and retrospective chart reviews
- Burden-of-illness and cost studies for the reimbursement dossier
- Regulatory support for TİTCK licensing submissions, with local experts
- Early access and compassionate use programme management
How it works
-
2 weeks
Access assessment
Where your product stands with TİTCK and SGK, and what evidence is missing.
-
Evidence plan
Study design, sites and timeline.
-
Study
Ethics, data collection, analysis.
-
Dossier inputs
Report and tables ready for the reimbursement file.
Proof
- 50+ pharmacoeconomic studies
- Founded 1997
- ICH-GCP
- ISO 9001
- ISO/IEC 27001
Send us your product. We will tell you what Turkey needs to see before it pays for it.
Reply within one business day.
Book your market access call
Sources
- 1. Koç İ., "The causal relationship between consanguineous marriages and infant mortality in Turkey", Journal of Biosocial Science 49(6), 2017 — Turkey Demographic and Health Survey data: 24% of marriages consanguineous. https://www.cambridge.org/core/journals/journal-of-biosocial-science/article/causal-relationship-between-consanguineous-marriages-and-infant-mortality-in-turkey/8833E2FA100581DB70C4CDF4D9BA3D16